• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,000
83
62
59
47

COUNTRY

57
19
10
7
5

CATEGORIES

  • 85
  • 124
  • 66
  • 65
  • 37
  • 36
  • 12
  • 12
  • 12
  • 18

PRICE

139
614
1,000
2,706

PUBLISHED

9
149
647
2,706

PRODUCT TYPE

2,599
87
12
7
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)

“GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline...

May 2014
FROM

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder...

April 2014
FROM

Ureter Cancer Global Clinical Trials Review, H1, 2014

Ureter Cancer Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Ureter Cancer Global Clinical Trials Review, H1, 2014" provides data on the Ureter Cancer clinical trial scenario....

April 2014
FROM

Anaplastic Thyroid Cancer - Pipeline Review, H1 2014

Anaplastic Thyroid Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Pipeline Review, H1 2014’, provides an overview of the Anaplastic Thyroid Cancer’s...

April 2014
FROM

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014’, provides an overview of...

April 2014
FROM

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2014’, provides an overview of...

April 2014
FROM

Soft Tissue Sarcoma - Pipeline Review, H1 2014

Soft Tissue Sarcoma - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Soft Tissue Sarcoma - Pipeline Review, H1 2014’, provides an overview of the Soft Tissue Sarcoma’s therapeutic pipeline. This...

April 2014
FROM

Supratentorial Glioma Global Clinical Trials Review, H1, 2014

Supratentorial Glioma Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Supratentorial Glioma Global Clinical Trials Review, H1, 2014" provides data on the Supratentorial...

April 2014
FROM

Ovarian Cancer - Pipeline Review, H1 2014

Ovarian Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Ovarian Cancer - Pipeline Review, H1 2014’, provides an overview of the Ovarian Cancer’s therapeutic pipeline. This report...

April 2014
FROM

Squamous Cell Carcinoma - Pipeline Review, H1 2014

Squamous Cell Carcinoma - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Squamous Cell Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Squamous Cell Carcinoma’s therapeutic...

April 2014
FROM

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014’, provides an overview of the B-Cell...

April 2014
FROM

Cutting Edge Therapies for Cancer in the 21st Century

Tailored cancer targeted therapy is becoming an emerging objective of today In this book, a constructive group of cancer research experts bring the reader their shared vision, to give an extensive and...

April 2014

Uterine Cancer - Pipeline Review, H1 2014

Uterine Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Uterine Cancer - Pipeline Review, H1 2014’, provides an overview of the Uterine Cancer’s therapeutic pipeline. This report...

April 2014
FROM

Neuroendocrine Tumors - Pipeline Review, H1 2014

Neuroendocrine Tumors - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Neuroendocrine Tumors - Pipeline Review, H1 2014’, provides an overview of the Neuroendocrine Tumors’s therapeutic...

April 2014
FROM

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2014

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Cutaneous T-Cell Lymphoma’s...

April 2014
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the...

April 2014
FROM

Urethral Cancer Global Clinical Trials Review, H1, 2014

Urethral Cancer Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Urethral Cancer Global Clinical Trials Review, H1, 2014" provides data on the Urethral Cancer clinical trial...

April 2014
FROM

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014’, provides an overview...

April 2014
FROM

Verrucous Carcinoma Global Clinical Trials Review, H1, 2014

Verrucous Carcinoma Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Verrucous Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Verrucous Carcinoma...

April 2014
FROM

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2014

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia - Pipeline Review, H1 2014’, provides an overview of the Waldenstrom Macroglobulinemia’s...

April 2014
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)